Conclusions
Low dose (500mg) intravenous FCM treatment was not equivalent to 1000mg within a 5% margin for successful correction of ID in pregnancy. A single 1000mg does represents an efficient and effective method to clinically manage ID and IDA in pregnancy. A lower dose approach requires ongoing monitoring to ensure adequate iron stores are reached and sustained. Both doses had no adverse impact on neonatal or child outcomes.